Elevated Serum IgE: A Comprehensive Overview

Normal IgE Levels

1. Conditions Causing Elevated Serum IgE

Allergic/Atopic Diseases (most common in industrialized/semi-urban settings)

• Allergic rhinitis (hay fever)
• Bronchial asthma (especially allergic asthma)
• Atopic dermatitis (eczema)
• Allergic bronchopulmonary aspergillosis (ABPA) - characteristically very high IgE (>1000 IU/mL), used diagnostically
• Food allergy / anaphylaxis
• Urticaria (chronic spontaneous urticaria)
• Eosinophilic gastroenteritis / eosinophilic esophagitis

Parasitic/Infectious Causes

• Helminth infections (the primary non-allergic cause worldwide): roundworms (Ascaris), hookworms (Ancylostoma, Necator), Toxocara, Strongyloides, filariasis, Schistosoma, Echinococcus, Paragonimus
• Tropical pulmonary eosinophilia (TPE) - due to Wuchereria bancrofti/Brugia malayi
• Visceral larva migrans

Immunodeficiency Syndromes

• Autosomal Dominant Hyper-IgE Syndrome (AD-HIES, Job's syndrome) - STAT3 mutation; recurrent skin/lung infections, pneumatoceles, facial dysmorphia, retained primary teeth, hyperextensibility, scoliosis - Harrison's 22E
• Autosomal Recessive Hyper-IgE Syndrome - DOCK8 mutation; severe viral/fungal infections, low T and B lymphocyte counts
• Omenn syndrome (SCID variant)
• Wiskott-Aldrich syndrome

Inflammatory/Autoimmune

• IgG4-related disease (elevated IgG4 and IgE, eosinophilia)
• Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)
• Kimura disease

Malignancy

• Hodgkin's lymphoma
• IgE myeloma (rare)
• Certain T-cell lymphomas

Other

• HIV infection
• Graft-versus-host disease (GVHD)
• Drug hypersensitivity reactions
• Alcoholic liver disease

2. When to Consider Biologics

1. Moderate-to-severe allergic asthma not adequately controlled on inhaled corticosteroids (ICS) + long-acting beta-agonists (LABA) - Goldman-Cecil Medicine
2. Patients who cannot stop oral steroids without recurrent uncontrolled bronchospasm (steroid-dependent asthma)
3. Severe allergic rhinitis refractory to standard therapy
4. Chronic spontaneous urticaria (CSU) unresponsive to antihistamines
5. Severe atopic dermatitis not controlled by topical therapy
6. Eosinophilic asthma with blood eosinophils > 150-300 cells/uL despite maximal ICS therapy
7. ABPA with persistent elevated IgE and radiologic/clinical activity

3. Biologics Available, Their Indications, and Contraindications

A. Omalizumab (Xolair) - Anti-IgE

• Mechanism: Humanized monoclonal antibody that binds free circulating IgE, depletes it, and downregulates FceRI (high-affinity IgE receptor) on mast cells and basophils - K.J. Lee's Otolaryngology
• Indications:
  • Severe persistent allergic asthma, age > 12 years, serum IgE 30-700 IU/mL
  • Chronic spontaneous urticaria (300 mg/month regardless of IgE)
  • Severe allergic rhinitis (clinical trials support benefit)
• Dosing: Weight- and IgE-level-based; every 2 or 4 weeks subcutaneously
• Effect on IgE: Decreases free (unbound) IgE; total IgE may paradoxically remain elevated for up to 1 year post-omalizumab (Katzung Pharmacology 16th ed.)
• Absolute Contraindications:
  • Known hypersensitivity/anaphylaxis to omalizumab
  • Serum IgE < 30 IU/mL or > 700 IU/mL (outside dosing range for asthma indication)
  • Non-allergic asthma
  • Parasitic infections (use caution - may reduce anti-parasite immunity)
• Adverse effects: Anaphylaxis (monitor 30-60 min post-injection), local site reaction, arteriothrombotic events

B. Mepolizumab (Nucala) - Anti-IL-5

• Mechanism: Humanized anti-IL-5 antibody; inhibits eosinophil differentiation, maturation, migration, survival
• Indications: Severe eosinophilic asthma with blood eosinophils > 150 cells/uL; eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
• Dose: 100 mg SC every 4 weeks
• Reduces exacerbations ~50%; glucocorticoid-sparing
• Contraindications: Active/untreated parasitic infections; hypersensitivity

C. Reslizumab (Cinqair) - Anti-IL-5

• Similar to mepolizumab; 3 mg/kg IV every 4 weeks
• For severe eosinophilic asthma inadequately controlled on ICS

D. Benralizumab (Fasenra) - Anti-IL-5 Receptor alpha

• Binds IL-5 receptor alpha; causes near-complete depletion of eosinophils and basophils
• 30 mg SC every 4-8 weeks; ~50% reduction in exacerbations
• Contraindications: Hypersensitivity; active helminthic infection

E. Dupilumab (Dupixent) - Anti-IL-4/IL-13 receptor alpha

• Blocks shared alpha subunit of IL-4 and IL-13 receptor
• Indications: Moderate-to-severe asthma; moderate-to-severe atopic dermatitis; chronic rhinosinusitis with nasal polyps; eosinophilic esophagitis
• 300 mg SC every 2 weeks
• Contraindications: Hypersensitivity to dupilumab

F. Tezepelumab (Tezspire) - Anti-TSLP

• Human monoclonal antibody against thymic stromal lymphopoietin (TSLP)
• 210 mg SC every 4 weeks
• Unique: Effective regardless of blood eosinophil level; broadest biologic for severe asthma
• Contraindications: Hypersensitivity

General Absolute Contraindications for Biologics (All Classes)

• Active serious infection (including active parasitic helminthic infection)
• Known hypersensitivity to the specific biologic
• Pregnancy (relative for most; dupilumab and others - limited data; individual risk-benefit)
• Active malignancy (relative)
• Live vaccines should be administered before starting biologics

4. Drugs That Lower Circulating Serum IgE Levels

5. Clinical Scenario: Patient with IgE = 700 IU/mL + Recurrent Pharyngitis, Sore Throat, Runny Nose

Step 1 - Most Likely Diagnosis: Allergic Rhinitis with Post-Nasal Drip

• IgE of 700 is significantly elevated and fits the allergic range
• Runny nose + sore throat + recurrent pharyngitis is the classic picture of allergic rhinitis with post-nasal drip - mucus dripping down the posterior pharynx causes chronic pharyngeal irritation and recurrent "pharyngitis"
• This is often misdiagnosed as recurrent bacterial tonsillitis/pharyngitis and treated with repeated antibiotics

Step 2 - Rule Out/Consider

Recommended Workup

1. Detailed allergy history - triggers, seasonality, family history of atopy
2. Eosinophil count (CBC with differential) - eosinophilia points toward allergy or parasites
3. Specific IgE (RAST/ImmunoCAP) or skin prick test to common aeroallergens (house dust mite, cockroach, mold, pollen) - the most relevant in India
4. Stool examination / serology for helminthic parasites (Ascaris, hookworm, Toxocara, Strongyloides) if eosinophilia present
5. Nasal endoscopy - assess for polyps, adenoid hypertrophy, posterior drainage
6. Total IgE trend over time (is it rising?)

Management

• If allergic rhinitis confirmed: intranasal corticosteroids (first-line) + antihistamines; saline nasal irrigation
• Allergen immunotherapy (AIT) if long-term control is needed - this also gradually lowers IgE
• Treat post-nasal drip specifically: this will resolve the "pharyngitis"
• If parasitic: appropriate anti-helminthic (albendazole/mebendazole/ivermectin)
• Omalizumab: consider if severe uncontrolled allergic asthma/rhinitis with IgE in 30-700 range - this patient's IgE of 700 is at the upper limit of the dosing range for omalizumab; it is still eligible for allergic asthma indication but would need weight-based dose calculation

6. Most Common Cause of High Serum IgE in Young Adults in India

• Ascaris lumbricoides (roundworm) - extremely prevalent
• Hookworm (Ancylostoma duodenale) - common in tropical soil
• Strongyloides stercoralis
• Tropical Pulmonary Eosinophilia (TPE) due to filarial species - highly characteristic of the Indian subcontinent

• Urbanization, air pollution, increased indoor allergens (house dust mite, cockroach - the #1 allergen in India)
• Periplaneta americana (cockroach) is the single most sensitizing aeroallergen in Indian urban populations
• Prevalence of allergic rhinitis in India is estimated at 20-30% in urban young adults

1. Allergic rhinitis / atopic disease (most common in urban settings)
2. Helminthic infection (more common in rural/semi-urban)
3. Bronchial asthma (often co-existing with rhinitis)
4. Atopic dermatitis

Key clinical pearl for India: Always check a CBC with differential when IgE is elevated. If eosinophilia (> 500/uL) is present alongside elevated IgE, parasitic infection must be actively ruled out before attributing the picture purely to allergy. Both conditions can coexist, and treating the parasite alone may normalize IgE substantially.

• Allergic/Atopic (blue) - mild-to-moderate eosinophilia, positive specific IgE, trigger history. Escalate from standard therapy (intranasal steroids, antihistamines, ICS+LABA) to biologics when uncontrolled. Omalizumab is the anchor biologic here (IgE 30-700 IU/mL). Dupilumab for atopic dermatitis and asthma. Eosinophilic asthma gets anti-IL-5 agents.
• Parasitic/Infectious (green) - marked eosinophilia (often > 1000/uL), tropical/rural exposure. Treat the parasite first (albendazole, ivermectin, DEC for filaria). Recheck IgE at 3 months post-treatment. Do NOT start omalizumab until parasites are cleared - it may reduce anti-parasite immunity.
• Immunodeficiency/Rare (orange-red) - recurrent bacterial/fungal/viral infections disproportionate to the clinical context. Hyper-IgE syndrome (STAT3/DOCK8 mutations), IgG4-related disease, malignancy, Omenn syndrome. These need subspecialty referral.